DIREZIONE
RICERCATORI
ASSOCIATI
AMMINISTRAZIONE
TECNICI

 INFO

Simona Camorani
Ricercatore

Via T. de Amicis 95, III piano - 80145 Napoli

+ 39-0815455751

s.camorani@ieos.cnr.it

 Research Interests

 Short CV

 Selected Publications

  1. Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov I V, Fedele M, Zannetti A, De Lorenzo C, Cerchia L. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. J Exp Clin Cancer Res. 2020;39(1):180. doi:10.1186/s13046-020-01694-9.
  2. Camorani S, Granata I, Collina F, Leonetti F, Cantile M, Botti G, Fedele M, Guarracino MR, Cerchia L. Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer. iScience. 2020;23 (4):100979. doi:10.1016/j.isci.2020.100979.
  3. Passariello M, Camorani S, Vetrei C, Ricci S, Cerchia L, De Lorenzo C. Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. Cancers (Basel). 2020;12(2):331. doi:10.3390/cancers12020331.
  4. Passariello M, Camorani S, Vetrei C, Cerchia L, De Lorenzo C. Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing. Cancers (Basel). 2019;11(9):1268. doi:10.3390/cancers11091268.
  5. Vitiello M, Palma G, Monaco M, Bello AM, Camorani S, Francesca P, Rea D, Barbieri A, Chiappetta G, De Vita G, Cerchia L, Arra C, Fedele M. Dual Oncogenic/Anti-Oncogenic Role of PATZ1 in FRTL5 Rat Thyroid Cells Transformed by the Ha-RasV12 Oncogene. Genes (Basel). 2019;10(2):127. doi:10.3390/genes10020127
  6. Camorani S, Hill BS, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L. Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer. Theranostics. 2018; 8(18):5178-5199. doi: 10.7150/thno.27798.
  7. Camorani S, Fedele M, Zannetti A, Cerchia L. TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities. Pharmaceuticals (Basel). 2018; 11(4). pii: E123. doi: 10.3390/ph11040123.
  8. Camorani S, Crescenzi E, Fedele M, Cerchia L. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications. Biochim Biophys Acta. 2018; 1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003.
  9. Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E. Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB. Oncotarget. 2018; 9(28):19929-19944. doi: 10.18632/oncotarget.24961.
  10. Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, Arra C, Crescenzi E, Cerchia L, De Caro MLDB, Fedele M. PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget. 2017; 8(35):59282-59300. doi: 10.18632/oncotarget.19546.
  11. Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A. Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer. Theranostics. 2017; 7(14):3595-3607. doi: 10.7150/thno.18974.
  12. Monaco I*, Camorani S*, Colecchia D*, Locatelli E, Calandro P, Oudin A, Niclou S, Arra C, Chiariello M#, Cerchia L#, Comes Franchini M#. Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. J Med Chem. 2017; 60(10):4510-4516. doi: 10.1021/acs.jmedchem.7b00527. *co-first authorship
  13. Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L. Aptamer-mediated impairment of EGFR-integrin avβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers. Sci. Rep. 2017; 7, 46659. doi: 10.1038/srep46659.
  14. Camorani S, Cerchia L. Highlighting the potential of aptamer-based strategy to treat EGFRvIII-positive glioblastoma. Can Cell Microenviron 2016; 3: e1314. doi: 10.14800/ccm.1314.
  15. Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Oncotarget. 2015; 6(35):37570-87. doi: 10.18632/oncotarget.6066.
  16. Camorani S, Cerchia L. Oligonucleotide aptamers for glioma targeting: an update. Cent Nerv Syst Agents Med Chem. 2015; 15(2):126-37. doi: 10.2174/1871524915666150430122525.
  17. Camorani S, Esposito CL, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. Mol Ther. 2014; 22(4):828-41. doi: 10.1038/mt.2013.300.
  18. Cerchia L, Esposito CL, Camorani S, Rienzo A, Stasio L, Insabato L, Affuso A, de Franciscis V. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther. 2012; 20(12):2291-303. doi: 10.1038/mt.2012.163.
  19. Cerchia L, Esposito CL, Camorani S, Catuogno S, de Franciscis V. Coupling Aptamers to Short Interfering RNAs as Therapeutics. Pharmaceuticals (Basel) 2011; 4(11):1434-1449. doi: 10.3390/ph4111434.

 Collaborations



IEOS - Istituto per l'endocrinologia e l'oncologica sperimentale "Gaetano Salvatore" © 2025